Business
AbbVie plans to build out its presence in obesity market
Jan 14 (Reuters) - AbbVie said on Wednesday it is seeking to expand its presence in the fast-growing market for obesity treatments, leaning on the weight-loss drug it licensed last year from Danish biotech Gubra. Gubra's drug, GUBamy, mimics the hormone amylin and could be used as an alternative to popular GLP-1 drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound to help people lose more weight with fewer side effects.
Business
Coffee Prices Finish Higher on Brazil Cop Concerns
March arabica coffee (KCH26 ) on Tuesday closed up +4.20 (+1.18%). March ICE robusta coffee (RMH26 ) closed up +36 (+0.92%). Coffee prices settled higher on Tuesday amid concerns that excessive dryness in Brazil could lead to smaller coffee yields. Last Thursday, arabica rallied to a 1-month high due to...
Business
It's your last chance to subscribe to Paramount+ before they raise their prices: Here's how to lock in current pricing
Here's how to lock in Paramount+'s current pricing before they raise their rates.
Business
Thermo Fisher wins contracts as pharma shifts production to US, CEO says
By Sneha S K and Gnaneshwar Rajan Jan 13 (Reuters) - Thermo Fisher Scientific's pharmaceutical services business has won a number of contracts to help its customers move production from Europe or Asia to the U., the medical equipment maker's CEO, Marc Casper, said on Tuesday.
Business
AstraZeneca to acquire Modella AI to speed oncology drug research
SAN FRANCISCO, Jan 13 () - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs. The companies did not disclose financial terms.
Business
Illumina unveils dataset to speed up AI-powered drug discovery
Jan 13 () - Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help accelerate drug discovery through artificial intelligence. The company said it was partnering with drugmakers AstraZeneca, Merck and Eli Lilly for its Billion Cell Atlas, which will train advanced AI models at scale and advance research into fundamental disease mechanisms that have previously been out of reach.
Business
Revvity says it will exceed 2025 profit forecast range
Jan 12 () - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
Business
Why is Jerome Powell being investigated? Making sense of the DOJ's probe into the Federal Reserve chair.
The head of the nation's most important financial institution has been the target of relentless criticism from President Trump.
Business
Advocacy groups react after Mattel introduces 1st Barbie doll with autism
Mattel announced a new Barbie doll, the first with autism, on Sunday.
Business
Medtronic has 'significant firepower' for multiple acquisitions, executives say
Jan 12 () - Medtronic has "significant firepower" to pursue acquisitions as the medical device maker evaluates opportunities to expand its portfolio, executives said at a major industry conference that kicked off on Monday in San Francisco. The medical device maker has been eyeing tuck-in deals as it seeks to diversify its portfolio, particularly in cardiology and neuroscience, with CEO Geoff Martha in November saying that they would prefer companies in "early stage or close to market.